Drug intelligence / Profile preview

GN8P

Development stage: Preclinical
Modality: Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

GN8P is a N-acetyl-D-glucosamine-coated polyamidoamine dendrimer that acts as a ligand for the activating receptors NKR-P1A and NKR-P1C on natural killer (NK) cells. It has demonstrated antitumor activity in rodent models by enhancing NK cell-mediated cytotoxicity, promoting antigen-specific antibody responses, increasing interferon-gamma production in NK cells, and increasing the number and activation of plasma cells and antigen-presenting B lymphocytes. Its principal studied indication is as an immunomodulatory anticancer agent in preclinical melanoma and colorectal cancer models[1][2].

Other names: N-acetyl-D-glucosamine-coated polyamidoamine dendrimer

Targets

Klrb1c (Killer cell lectin-like receptor subfamily B member 1C)

Beyond the preview

Go deeper on GN8P.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GN8P.

Explore the full profile